Name: Piclib 125mg
SKU: 24436
Availability: InStock

📋 Product Overview Table

🌐 Specification	🧾 Details
💊 Active Ingredient	Palbociclib 125 mg
🏭 Manufacturer	Hetero Drugs Ltd
💊 Dosage Form	Oral Capsule
📦 Packaging	21 Capsules in 1 Bottle
🩺 Indication	HR+/HER2- Advanced or Metastatic Breast Cancer
🇺🇸 US Brand Equivalent	Ibrance (Pfizer)
⏱️ Delivery Time	6 to 15 business days

🧬 Introduction – What is Piclib 125 mg?

Piclib 125 mg, manufactured by Hetero Drugs Ltd, is a targeted anticancer medication that contains Palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor. It is primarily used in combination with hormonal therapy for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in women and men.

As a generic version of the branded drug Ibrance, Piclib offers an affordable and accessible alternative without compromising efficacy. It is widely used across oncology centers and is available for international shipping, including to the USA, UK, and Australia.

🎥 Educational Video Overview

📺 “Targeted Cancer Therapy: How CDK4/6 Inhibitors Work”
🎬 Video Placeholder – Covers how Palbociclib targets cancer cells and benefits patient survival.

🎙️ Explains the synergy of Palbociclib with hormonal therapy in breast cancer treatment.

🔬 Mechanism of Action – How Palbociclib Works

Palbociclib selectively inhibits CDK4 and CDK6, proteins that regulate cell cycle progression. By blocking these kinases, it prevents the growth of cancer cells, slowing tumor progression.

⚗️ Biological Action	🔍 Effect on Cancer Cells
Inhibits CDK4/6 activity	Arrests tumor cells in G1 phase
Reduces proliferation of tumor	Prevents uncontrolled cell division
Enhances endocrine therapy effect	Improves response to drugs like letrozole and fulvestrant

💊 Dosage & Administration

📋 Instruction	💊 Details
Standard Dose	125 mg once daily for 21 consecutive days, followed by 7 days off
Combination Therapy	Used with aromatase inhibitors (e.g., letrozole) or fulvestrant
Administration	Oral, with food
Treatment Cycle	28-day cycle

Note: Blood cell counts should be monitored regularly during therapy.

⚠️ Side Effects & Warnings

💥 Common Side Effects	❗ Serious Reactions (Seek Medical Help)
Neutropenia, fatigue, nausea	Febrile neutropenia, severe infections, liver dysfunction
Diarrhea, hair thinning	Interstitial lung disease, pulmonary embolism
Loss of appetite	Anemia, thrombocytopenia

Avoid grapefruit and grapefruit juice while on this medication. Regular CBC monitoring is essential.

🧃 Storage Instructions

Store below 30°C (86°F)
Keep the bottle tightly closed
Protect from light and moisture
Keep out of reach of children

🌍 Availability & International Ordering

🌎 Country	📦 Import Rules	📑 Prescription Required
🇺🇸 USA	Import for personal use with valid prescription	✅ Yes
🇬🇧 UK	Permitted under MHRA personal import regulations	✅ Yes
🇦🇺 Australia	Allowed under TGA personal importation scheme	✅ Yes

Delivery Estimate: 6 to 15 business days

🔗 Related Indian Oncology Alternatives

💊 Product	🏭 Manufacturer	📖 Description
Ibrance 125 mg	Pfizer India Ltd	Original Palbociclib formulation approved for HR+/HER2- breast CA
Palnib 125 mg	Natco Pharma Ltd	Affordable Palbociclib generic with CDK4/6 inhibition
Sunitinib 50 mg	Cipla Ltd	Oral targeted therapy for renal cell carcinoma and GIST
Lenvima 4 mg	Eisai Pharmaceuticals	Tyrosine kinase inhibitor for thyroid, renal, and liver cancers
Everolimus 10 mg	Biocon Ltd	mTOR inhibitor for breast and renal cancer

📚 References & External Resources

🩺 Expert Opinion – Dr. Shalini Deshmukh, MD (Oncology)

“Palbociclib 125 mg represents a breakthrough in targeted therapy for breast cancer. Piclib offers a cost-effective solution in regions where affordability is critical, while maintaining comparable therapeutic benefit.”

⚠️ Disclaimer

This article is intended for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before starting or changing cancer medications.